How is your business helping to solve the health, social, or economic challenges created by COVID19?
We are developing a treatment for patients affected by COVID-19. PepVax, Inc. is developing a potent DNA-immunotherapy against SARS-CoV-2 based on its patented SMARTmid platform “engineering” required anti-SARS-CoV-2 Chimeric Antigen Receptor (CAR) T-cells inside patient
Does your business contribute most to recovery, response, or resilience?
Response - we're responding directly to issues caused or exacerbated by the COVID-19 outbreak.
What is the stage of your product development?
I do not have a physical product or prototype
What strengths does your team bring? Include skills and personal experience with the problem.
With over 40 years of combined experience in immunology, PepVax’s management team brings with it the ability to raise necessary funding, design in vitro trials in coordination with our outsourced partners, monitor the trials, and develop new technologies through cutting-edge research and development. Members of the management team have experience in setting up the necessary infrastructure for early-stage companies that will ultimately make them successful.Anton Dormer -CSO; formerly Professor at Washington Adventist University; M.D., UTESA; M.S. in Biotech, UMass-BostonDan Achinko -Senior Scientist, Research & Development; Ph.D., International Center of Insect Physiology and EcologyMahesh Narayanan -CEO; Biotechnology entrepreneur, M.S. in Biotechnology, University of Pennsylvania
What countries do you operate in?
United States
Is your company headquartered in a US "Opportunity Zone"?
No
